Raymond James & Associates’s Agile Therapeutics AGRX Stock Holding History

Raymond James & Associates’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13	Closed	-$25K	–	4326
2021 Q3	$25K	Hold	13	–	–	﹤0.01%	3987
2021 Q2	$36K	Hold	13	–	–	﹤0.01%	3944
2021 Q1	$56K	Sell	13 -1	-7%	-$5.41K	﹤0.01%	3845
2020 Q4	$81K	Hold	14	–	–	﹤0.01%	3588
2020 Q3	$86K	Buy	14 +2	+17%	+$11.5K	﹤0.01%	3399
2020 Q2	$65K	Hold	12	–	–	﹤0.01%	3353
2020 Q1	$44K	Buy	12 +3	+33%	+$17.2K	﹤0.01%	3329
2019 Q4	$43K	Buy	+9	New	+$31.4K	﹤0.01%	3565
2018 Q4	–	Sell	-6	Closed	-$5K	–	3736
2018 Q3	$5K	Hold	6	–	–	﹤0.01%	3604
2018 Q2	$6K	Buy	+6	New	+$21.1K	﹤0.01%	3542
2015 Q2	–	Sell	-14	Closed	-$253K	–	2463
2015 Q1	$253K	Buy	+14	New	+$245K	﹤0.01%	2262

Other funds holding AGRX

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James & Associates's AGRX Position: Q4 2021 in Review

Raymond James & Associates sold out of Agile Therapeutics (AGRX) in Q4 2021, closing a stake of 13 shares — an estimated $25K sold.

Raymond James & Associates first reported a position in AGRX in Q1 2015 and held it in 11 quarters. The position peaked at $253K in Q1 2015. 45 funds tracked by Wall St. Rank hold AGRX as of Q4 2021.

Raymond James & Associates reported no remaining Agile Therapeutics position as of Q4 2021 after selling out during the quarter.
Raymond James & Associates sold 13 Agile Therapeutics shares in Q4 2021, an estimated $25K.
Raymond James & Associates first reported a position in Agile Therapeutics in Q1 2015 and held it in 11 quarters.
Raymond James & Associates's Agile Therapeutics position peaked at $253K in Q1 2015.
45 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.